Display options
Share it on

Int J MS Care. 2021 Jul-Aug;23(4):143-149. doi: 10.7224/1537-2073.2020-007. Epub 2020 Oct 16.

Effectiveness of Three-Dimensional Multiple-Object Tracking in Patients with Multiple Sclerosis: A Pilot Trial.

International journal of MS care

Sebastian Harenberg, Jennifer St Onge, Jill Robinson, Omorowa Eguakun, Anthony Feinstein, Kim Dorsch, Rumit Singh Kakar, Raghig Abdulhakim, Zia Rehman, Melad Shawush, Vinesh Pillay

PMID: 34483752 PMCID: PMC8405148 DOI: 10.7224/1537-2073.2020-007

Abstract

BACKGROUND: Computerized cognitive training remains an attractive supplemental modality to enhance rehabilitation in multiple sclerosis (MS). The objective of the present study was to assess the usability of three-dimensional multiple-object tracking (3D-MOT) in patients with MS.

METHODS: In this pilot study, 16 patients with relapsing-remitting MS and nine age-matched controls participated in four 30-minute training sessions of 3D-MOT. Computerized neuropsychological tests, including driving readiness (ie, Useful Field of View) and cognitive function (ie, Stroop Color and Word Test, Paced Visual Serial Addition Test, Symbol Digit Modalities Test) were conducted at baseline and at the conclusion of training.

RESULTS: Although scoring lower in 3D-MOT, the MS group improved their 3D-MOT scores in similar magnitude as the control group. The 3D-MOT training led to significant improvements in driving readiness in the MS group. Taken together, 3D-MOT training showed similar effectiveness in patients with MS as in age-matched controls.

CONCLUSIONS: Training with 3D-MOT may be an accessible and remotely administrable supplement to cognitive rehabilitation protocols for patients with MS.

© 2021 Consortium of Multiple Sclerosis Centers.

Keywords: Attention; Cognition; Multiple sclerosis (MS); Multiple-object tracking; Rehabilitation

Conflict of interest statement

Financial Disclosures: Dr Feinstein has received speakers’ honoraria from Novartis, Merck Serono, Roche, and Sanofi Genzyme. The other authors declare no conflicts of interest.

References

  1. Neurorehabil Neural Repair. 2013 May;27(4):284-95 - PubMed
  2. Schweiz Arch Neurol Psychiatr (1985). 1994;145(3):35-6 - PubMed
  3. J Neurol Sci. 2006 Jun 15;245(1-2):147-51 - PubMed
  4. Arch Phys Med Rehabil. 2018 Feb;99(2):390-407 - PubMed
  5. Optom Vis Sci. 2005 Aug;82(8):724-31 - PubMed
  6. J Neurol. 2013 Jun;260(6):1452-68 - PubMed
  7. Trends Cogn Sci. 2000 Oct 1;4(10):383-391 - PubMed
  8. Mult Scler. 2014 Jan;20(1):91-8 - PubMed
  9. Neurology. 1991 May;41(5):692-6 - PubMed
  10. Neuroreport. 2012 May 30;23(8):469-73 - PubMed
  11. PLoS One. 2017 Oct 10;12(10):e0185909 - PubMed
  12. J Am Optom Assoc. 1993 Jan;64(1):71-9 - PubMed
  13. Dev Sci. 2018 Nov;21(6):e12670 - PubMed
  14. Clin Rehabil. 2018 Feb;32(2):243-254 - PubMed
  15. J Clin Exp Neuropsychol. 2005 Jul;27(5):529-43 - PubMed
  16. Can J Neurol Sci. 2017 Sep;44(5):547-555 - PubMed
  17. J Surg Educ. 2016 May-Jun;73(3):386-90 - PubMed
  18. Neuroimage. 2001 Jan;13(1):68-75 - PubMed
  19. J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):455-62 - PubMed
  20. Arch Neurol. 2004 Feb;61(2):226-30 - PubMed
  21. Mult Scler. 2009 Sep;15(9):1077-84 - PubMed
  22. Mult Scler. 2008 Nov;14(9):1250-61 - PubMed
  23. Eur J Neurol. 2014 Feb;21(2):281-6 - PubMed
  24. Arch Phys Med Rehabil. 2002 Aug;83(8):1123-9 - PubMed
  25. Arch Neurol. 1980 Sep;37(9):577-9 - PubMed
  26. Arch Neurol. 2001 Oct;58(10):1602-6 - PubMed
  27. Int J Nurs Stud. 2003 Sep;40(7):719-24 - PubMed

Publication Types